Key result
Semaglutide, rosuvastatin, and ezetimibe linked to slower AVA progression in non-diabetic AS.
Why the study?
Predictors of aortic stenosis progression were investigated in patients monitored with clinical controls, echocardiograms, and biochemical variables.
Does semaglutide combined with lipid-lowering therapy slow the progression of aortic valve stenosis in non-diabetic patients with obesity?
Cohort (n=20)
Does semaglutide combined with lipid-lowering therapy slow the progression of aortic valve stenosis in non-diabetic patients with obesity?
Semaglutide combined with intensive lipid-lowering therapy may be associated with a slowing of echocardiographic progression of aortic stenosis in non-diabetic patients with obesity.
Answers are grounded in this paper and cite their sources.
May support semaglutide plus lipid-lowering in obese non-diabetic aortic stenosis; hypothesis-generating and requires randomized confirmation before practice change.
Abstract We investigated predictors of aortic stenosis (AS) progression in 20 consecutive patients (pts) every 6 months for 24 months with clinical controls, echocardiograms and biochemical variables. The changes evuated were: every 6 months clinical status and mean gradient [MG], peak velocity [PV], peak gradient [PG], or aortic valve area [AVA]); at baseline and after 24 months: calcium score [AVC] at computed tomography. Pts with obesity (BMI ≥30.0 kg/m²) and/or hip circumference /height ratio ›0.5 were treated with Glucagon–Like Peptide–1 Receptor Agonist semaglutide (GLP1–RA) subcutaneously once weekly. During the first 16 weeks, the dose of semaglutide was gradually escalated from 0.25 mg once weekly until the target dose. Pts with diabetes mellitus were excluded from the study. Pts with LDL levels › 110 mg were treated with rosuvastatin 20 mg + ezetimibe 10 mg. Resuts The pooled annualized progression of MG was +4.80 mm Hg (95% CI: 2.80–5.41 mm Hg), AVA −0.10 cm2 (95% CI: 0.06–0.12 cm2), PV +0.20 m/s (95% CI: 0.13–0.24 m/s), PG +8.8 mm Hg (95% CI: 5 –10.75 mm Hg), and AVC +160 AU (95% CI: 50–265 AU).The reduction in AVA per year was significantly related to initial AVA (r=0.42, P‹0.0001), mean aortic valve gradient (r=0.28, P=0.04), left ventricular (LV) outflow tract velocity (r=0.28, P=0.001), LV end–diastolic diameter (r=0.24, P=0.04) and to serum creatinine level (r=0.15, P=0.08).Pts with a faster rate of reduction in AVA had higher serum creatinine (P=0.04) and calcium (P=0.08) levels.Those with a serum LDL ›110 mg/dL had a rate of AVA reduction twice that of those with a lower cholesterol level (P=0.04). Initial AVA, current smoking, and serum calcium level were independent predictors of amount of AVA reduction per year. During a mean follow–up of 24 months, the changes in body weight, BMI, waist–to–hip ratio, and NYHA functional class correlated well with a slowing of the stenotic AVA progression in treated pts with semaglutide + rosuvastatin and ezetimibe (–0.10 ± 0.09 cm² /year). Conclusion Absolute and percentage AVA progression per year is greater in those with milder degrees of stenosis, higher body mass index, hip circumference / height ratio›0.5. Aortic stenosis progression is accelerated in the presence of smoking, hypercholesterolemia, lower BMI, and elevated serum creatinine and calcium levels. The use of GLP1–RA semaglutide plus rosuvastatin and ezetimibe seems to be a possible strategy to retard this process.
No takes yet. Share an insight, caveat, or question.
Marchetti et al. (2026) conducted a cohort in Aortic stenosis (n=20). Semaglutide, rosuvastatin, and ezetimibe was evaluated on Annualized progression of aortic valve area (AVA) (95% CI 0.06-0.12). In non-diabetic patients with aortic stenosis, treatment with semaglutide, rosuvastatin, and ezetimibe was associated with a slowing of aortic valve area progression.
Synapse has enriched 10 related papers. Consider them for comparative context: